uploads/2018/09/Chart-009-Pfizer-1.jpg

Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates

By

Updated

Pfizer’s earnings

Pfizer (PFE) reported revenue of ~$13.5 billion in the second quarter, a 4% YoY (year-over-year) rise in revenue compared to its revenue of ~$12.9 billion in the second quarter of 2017.

The chart above shows Pfizer’s quarterly revenue trend since the first quarter of 2017.

Article continues below advertisement

Revenue performance in the last quarter

Pfizer reported a rise of 4% in its top line to ~$13.47 billion, including a 2% rise in operating revenue and a 2% favorable impact of foreign exchange, in the second quarter. Its net adjusted income rose to ~$4.8 billion in the second quarter, an 18.8% rise compared to ~$4.1 billion in the second quarter of 2017.

The company’s sales in US markets totaled $6.23 billion in the second quarter, a 2% fall compared to its US sales of ~$6.35 billion in the second quarter of 2017. The fall in revenue was driven by 14% lower sales of essential health products at $1.6 billion during the quarter. However, the decrease was offset by a 3% increase in the sales of innovative health products at $4.6 billion.

The company’s international markets reported an 11% rise in revenue to ~$7.2 billion in the second quarter, including a 5% rise in operating revenue and a 6% favorable impact of foreign exchange.

Estimates for 2018

Analysts expect Pfizer to report a 3.2% YoY rise in revenue to $54.2 billion in 2018 compared to ~$52.5 billion in 2017. Its adjusted EPS are expected to rise ~12.8% to $2.99 in 2018.

The iShares US Healthcare ETF (IYH) holds 6.5% in Pfizer, 4.9% in Merck & Co. (MRK), 2.6% in Eli Lilly and Company (LLY), and 9.7% in Johnson & Johnson (JNJ).

Advertisement

More From Market Realist